Menu
Log in


Log in

Upcoming Webinars

    • Wednesday, September 10, 2025
    • 3:00 PM - 4:00 PM
    • Online
    • 98
    Register

    Wednesday, September 10, 2025 / 3:00 PM - 4:00 PM EDT

    Topic:
    HLA Basics

    Speaker:
    Dr. Jacquelyn Choate
    Rochester Regional

    Speaker Bio:
    coming

    Abstract:

    coming

    Objectives:

    coming

    Pricing:

    • Members: FREE (Registration is required.)
    • Non-Members: $45 per session & $130 entire series
    • Institutions: $75 per session & $200 entire series

    To receive member pricing, be sure to sign in.

    • Wednesday, September 17, 2025
    • 3:00 PM - 4:00 PM
    • Online
    • 98
    Register

    Wednesday, September 17, 2025 / 3:00 PM - 4:00 PM EDT

    Topic: 2025 BBANYS Annual Meeting Winning Posters

    This session will feature our 3 abstract poster winners from our 2025 BBANYS Annual Meeting. They will present their abstracts and be available for a discussion. We hope to see you there and celebrate our members' great scholarly work.

    Poster Title:

    A High-Sensitivity Flow Cytometry-Based Assay for Enhanced Detection of RBC Alloantibodies

    Presenter:

    Annie Qiu
    Research Associate
    Columbia University Medical Center

    Department of Pathology and Cell Biology

    Brief Bio:

    Annie Qiu is a research associate in the Lab of Transfusion Biology at Columbia University Medical Center. She earned her BS in Biology from Emory University, where she studied tyrosine kinase signaling pathways in pediatric leukemia in Dr. Douglas Graham’s lab. At Columbia, as a research technician under Dr. Krystalyn Hudson, she investigated alloimmunization following red blood cell (RBC) transfusions. Now working with Dr. Eldad Hod and Dr. Lisa Eisler as a clinical research coordinator, Annie leads studies on iron deficiency and RBC transfusions. Her work integrates her laboratory expertise with clinical research experience, with a focus on improving transfusion safety and advancing patient care


    Abstract:

    Routine agglutination-based assays detect only ~30% of induced red blood cell (RBC) alloantibodies, missing low-titer or evanescent antibodies and posing risks such as hemolytic disease, transfusion reactions, and transplant incompatibility. We developed a multiplex flow cytometry assay designed to improve sensitivity and reproducibility for detecting RBC alloantibodies. Compared with standard agglutination, the flow assay detected a positive sample to a 1:1600 dilution versus 1:128, with distinct cell populations and no signal interference. Reference ranges from 41 healthy controls defined positivity as mean fluorescence intensity >3 SD above the control mean, reproducible across several days. This assay reliably distinguishes between negative, intermediate-, and high-titer samples, offering improved detection of low-titer and evanescent antibodies. By capturing responses that may otherwise go undetected, it has the potential to enhance transfusion safety and inform patient management, though future studies should assess whether increased sensitivity justifies the added complexity and cost of implementation.

    ______________

    Poster Title:

    Successful Platelet Wastage Reduction


    Presenter:

    Ding Wen Wu, MD, PhD
    NYU Langone Hospital - Brooklyn

    Brief Bio:

    Ding Wen Wu, MD, PhD is a Clinical Professor of Pathology at NYU Grossman School of Medicine, and the Medical Director for Department of Pathology and Laboratory Medicine, at NYU Langone Hospital - Brooklyn, in New York, US. She also holds several other positions at NYU Langone Health. In addition, she is the Medical Director of Blood Bank for SBH Health System, Bronx, New York


    Abstract:

    coming

    ______________

    Poster Title:

    Clinical Appropriateness of Von Willebrand Factor Testing in an Academic Medical Center

    Presenter:

    Bianca Santonastaso
    University of Rochester Medical Center


    Brief Bio:

    coming


    Abstract:
    coming


    Pricing:

    • Members: FREE (Registration is required.)
    • Non-Members: $45

    To receive member pricing, be sure to sign in.

    • Wednesday, October 08, 2025
    • 3:00 PM - 4:00 PM
    • Online
    • 98
    Register

    Wednesday, October 8, 2025 / 3:00 PM - 4:00 PM EDT

    Topic:
    Adverse Outcomes of Blood Transfusions: Making the Case for Transfusion Avoidance in Modern Medical Practice

    Speaker:
    Mark T. Friedman, DO
    Clinical Associate Professor of Pathology
    Medical Director, Transfusion Service
    NYU Langone Health, NYU Grossman Long Island School of Medicine

    Speaker Bio:
    Dr. Mark Friedman is a Clinical Associate Professor and Medical Director of Transfusion Services at NYU Langone Health, NYU Grossman Long Island School of Medicine in Mineola, NY. He has been in practice for nearly 30 years and has taught, published extensively, and lectured in the area of patient blood management. He is a past president of BBANYS and currently serves as the BBANYS Newsletter Editor. He also is currently serving as the AABB Chair of the TSO/PBM Subsection.

    Abstract:

    Historically, transfusion risks were focused on transmissible diseases, especially hepatitis B and non-A-non-B hepatitis transmission (later identified as hepatitis C), which carried up to a 10% risk in the 1960’s and early 1970’s, and HIV after its emergence in the 1980’s. Although vigilance must be maintained in keeping these transmissible diseases and others (for example, West Nile virus and babesiosis) out of the blood supply, much of the focus has shifted to reducing non-transmissible disease risks, including mistransfusion of ABO incompatible blood, transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and platelet component bacterial contamination, among others. Yet, beyond even these recognized risks, transfusions are associated with thromboembolic complications (acute myocardial infarction and stroke), immunomodulatory effects (with increased risk of perioperative infections), and increased length of hospital stay, as evidenced by data from the Western Australia Patient Blood Management Program (PBM). As a result, the World Health Organization (WHO) has urgently called for global implementation of PBM, evidence-based strategies to conserve patients’ own blood and reduce the need for blood transfusions, in its October 2021 Policy Brief.

    Objectives:

    At the end of this session, the learner will be able to:

    1. Recognize historical transfusion risks, such as hepatitis and HIV, in the current context.
    2. Explain the transition of transfusion risk reduction from transmissible diseases to non-transmissible disease risks.
    3. Analyze the case for transfusion avoidance in transfusion risk reduction.

    Disclosures:

    None

    Pricing:
    • Members: FREE (Registration is required.)
    • Non-Members: $45 per session & $130 entire series
    • Institutions: $75 per session & $200 entire series

    To receive member pricing, be sure to sign in.

    • Wednesday, November 12, 2025
    • 3:00 PM - 4:00 PM
    • Online
    • 98
    Register

    Wednesday, November 12, 2025 / 3:00 PM - 4:00 PM EST

    Topic:
    Targeting FcRn in Hemolytic Disease of the Fetus and Newborn (HDFN)

    Speaker:
    Krystalyn E. Hudson
    Associate Professor of Pathology and Cell Biology, Co-Director of the Laboratory of Transfusion Biology
    Columbia University

    Speaker Bio:
    Dr. Krystalyn E. Hudson is an Associate Professor at Columbia University and Co-Director of the Laboratory of Transfusion Biology. She received her PhD from Emory University and completed her postdoctoral fellowship at Scripps Research Institute. Dr. Hudson’s NIH funded research focuses on immune responses to red blood cells (RBCs), which is relevant for transfusion medicine, pregnancy, and transplantation.

    Abstract:

    Hemolytic disease of the fetus and newborn (HDFN) arises when maternal IgG alloantibodies cross the placenta and target fetal red blood cells (RBCs), leading to their destruction and/or suppression. While anti-D alloantibodies are the most common cause—and can be prevented with anti-D immunoglobulin prophylaxis—HDFN can also result from other alloantibodies, such as those directed against the Kell blood group system, for which no approved prophylactic therapies currently exist.

    An emerging therapeutic approach for HDFN involves targeting the neonatal Fc Receptor (FcRn), a key regulator of IgG homeostasis and transplacental IgG transfer. FcRn protects IgG from lysosomal degradation and mediates its transport across epithelial barriers, including the placenta. Inhibiting FcRn accelerates IgG degradation and may reduce maternal IgG antibody from reaching the fetus, thereby attenuating HDFN severity. This presentation will review HDFN and discuss the current clinical landscape of FcRn-targeted therapies in HDFN.

    Objectives:

    At the end of this session, the learner will be able to:

    1. Describe HDFN
    2. Explain potential anti-D mechanisms
    3. Discuss the potential benefits and risks of targeting FcRn

    Disclosures:

    None

    Pricing:
    • Members: FREE (Registration is required.)
    • Non-Members: $45 per session & $130 entire series
    • Institutions: $75 per session & $200 entire series

    To receive member pricing, be sure to sign in.

    • Wednesday, December 10, 2025
    • 3:00 PM - 4:00 PM
    • Online
    • 98
    Register

    Wednesday, December 10, 2025 / 3:00 PM - 4:00 PM EST

    Topic:
    IgA Deficiency: To Wash or Not

    Speaker:
    Victoria Costa, MD
    Assistant Medical Director of Blood Bank
    NYU Langone Health Tisch Hospital

    Speaker Bio:
    Dr. Costa is currently Assistant Medical Director of the Blood Bank at NYU Langone Health Tisch Hospital, Clinical Assistant Professor in the Department of Pathology at NYU Grossman School of Medicine, Associate Program Director for the Clinical Pathology Residency Program and Medical Director of the 34th St and 38th St Clinical Laboratories at NYU Langone Health Perlmutter Cancer Center. She completed her medical education at The George Washington University, pathology residency at New York Presbyterian/Weill Cornell Medical Center, and transfusion medicine fellowship at Johns Hopkins Hospital. She is passionate about education and quality improvement efforts.

    Abstract:

    This webinar will review IgA deficiency, its diagnosis and management from the transfusion medicine perspective and ongoing areas of research.

    Objectives:

    At the end of this session, the learner will be able to:

    1. Define IgA deficiency and understand its relevance to transfusion medicine
    2. Understand how to provide transfusion support for those with IgA deficiency
    3. Learn about ongoing areas of research

    Disclosures:

    None

    Pricing:
    • Members: FREE (Registration is required.)
    • Non-Members: $45 per session & $130 entire series
    • Institutions: $75 per session & $200 entire series

    To receive member pricing, be sure to sign in.

BLOOD BANKS ASSOCIATION OF NEW YORK STATE
COPYRIGHT © 2025

CONTACT US
Phone: 866-397-8883
Fax: 651-317-8048
Email: bbanys@bbanys.org

ADDRESS
BBANYS
2345 Rice Street, Suite 220
St. Paul, MN 55113

Powered by Wild Apricot Membership Software